CTOs on the Move

Cyteir

www.cyteir.com

 
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cyteir.com
  • 128 Spring Street Building A, Suite 510
    Lexington, MA USA 02421
  • Phone: 857.285.4140

Executives

Name Title Contact Details

Funding

Cyteir raised $29M on 03/08/2018
Cyteir raised $40.2M on 10/15/2019
Cyteir raised $80M on 02/11/2021

Similar Companies

Innocoll

A specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet important healthcare challenges

GreenwichBiosciences

Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.

Healix

Healix Ltd is a Sugar Land, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoreLab Partners

CoreLab Partners is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capsugel

Capsugel is a Peapack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.